| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Amgen: No Lesson Learned From Merck
Posted on 04/17/2007 06:10:20 | Link | Post Comment
Douglas McIntyre
24/7 Wall St.
Amgen (AMGN) made an announcement that many investors already expected. The death rate in cancer patients using its anemia drug Aranesp was higher that those using a placebo.
According to Reuters: "The U.S. Food and Drug Administration last month slapped a strong new warning on the label of Aranesp and similar anemia drugs calling on doctors to use the lowest dose that can effectively avoid the need for blood transfusions."
Last week, Merck (MRK) came out with news that its new arthritis drug Arcoxia can cause blood pressure and heart problems. The FDA panel rejected the drug by a vote of 20-to-1.
The amazing thing about the large drug companies is that they seem surprised and disappointed with the results of these trials. In reality, it is a safe bet that they have a very good idea what side-affects these drugs may have long before they come to market.
So, why push them all the way to the FDA?
Good question.
Source: 247WallSt.com
RELATED READING:
- Amgen CFO Walks Out; Any More Execs Leaving?
- Someone At Merck Is Crazy
- Merck Does Investors a Favor
____________________
24/7 Wall St.
Amgen (AMGN) made an announcement that many investors already expected. The death rate in cancer patients using its anemia drug Aranesp was higher that those using a placebo.
According to Reuters: "The U.S. Food and Drug Administration last month slapped a strong new warning on the label of Aranesp and similar anemia drugs calling on doctors to use the lowest dose that can effectively avoid the need for blood transfusions."
Last week, Merck (MRK) came out with news that its new arthritis drug Arcoxia can cause blood pressure and heart problems. The FDA panel rejected the drug by a vote of 20-to-1.
The amazing thing about the large drug companies is that they seem surprised and disappointed with the results of these trials. In reality, it is a safe bet that they have a very good idea what side-affects these drugs may have long before they come to market.
So, why push them all the way to the FDA?
Good question.
Source: 247WallSt.com
RELATED READING:
- Amgen CFO Walks Out; Any More Execs Leaving?
- Someone At Merck Is Crazy
- Merck Does Investors a Favor
____________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
- Millionaire Now! by Larry Nusbaum
- Ludwig von Mises Institute
- Credit Bloggers
- Don't Mess With Taxes
- Invest2Success
- Poor and Stupid
Examples
Morpheus Trading - Mon Jul 21, 2008 08:33AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
Morpheus Trading - Mon Jul 21, 2008 08:31AM
NOTE: Please click on the charts below to enlarge them i [read more]
NOTE: Please click on the charts below to enlarge them i [read more]
Millionaire Now! by Larry Nusbaum - Fri Jul 18, 2008 08:23AM
U.S. stock futures rebound on Citigroup results"S&a [read more]
U.S. stock futures rebound on Citigroup results"S&a [read more]
<< My Home | TheMoneyBlogs Home